Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Pharmacogenet Genomics. 2017 Oct;27(10):378–385. doi: 10.1097/FPC.0000000000000302

Table 2. SNPs previously associated with ERBB2 cardiotoxicity (Arms BC).

Association analyses were performed assuming an additive effect in both linear and logistic regression models. For logistic regression, we report genotype counts, odds ratio (OR) and P-values (P) using the more stringent definition of cases as per Gomez Pena et al, 2015: Decrease of at least 10% points from baseline with a resulting LVEF of less than 50% or decrease of 15% with respect to baseline, or any decrease resulting in LVEF less than 45% at least once during the treatment or clinical manifestation of CHF.

Linear Max drop in LVEF Logistic LVEF literature
SNP ID AA change Beta, L95-U95 P genotype case genotype con OR, L95-U95 P
rs1136201 I655V −0.33 (−1.07 to 0.41) 0.39 GG=11 GG=39 0.941 (0.71 to 1.25) 0.67
GA=59 GA=228
AA=103 AA=360
rs1058808 P1170A −0.45 (−1.14 to 0.24) 0.20 CC=21 CC=65 1.034 (0.80 to 1.34) 0.80
CG=78 CG=293
GG=73 GG=268